Plain-English translation of NCT06889610 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination approach for treating advanced cancers (colorectal cancer, triple-negative breast cancer, and melanoma) that have spread to the liver. The study combines a procedure called multimodal ablation — which uses heat to destroy tumors — with an immunotherapy drug called pucotenlimab. Researchers believe this combination may work better than current treatments by activating your immune system to fight remaining cancer cells.
Current treatments for cancer that has spread to the liver don't work well enough for many patients. Researchers believe that destroying tumors with heat can trigger your body's immune system, and combining this with immunotherapy medication could break through these treatment limitations.
You likely qualify if…
You likely don't qualify if…
You would receive the multimodal ablation procedure to destroy selected tumors in your liver, followed by treatment with the immunotherapy medication pucotenlimab. The study will track how well this combination works and monitor you for side effects through clinic visits and blood tests. Your specific schedule and duration will depend on how you respond to treatment, but the trial involves ongoing assessments to measure tumor response and your overall health.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China